And I will say that we are making a really focused effort to drive our portfolio and innovation and new launches OUS to be more effective competing against that market.
Unidentified Analyst: Great. Just following up on Mobi, I am wondering, like, any early signs of adoption? And then I know the integration with G7 is going to be a big turning point, I guess is that when you are going to really start to see some revenue contribution? Thank you.
John Sheridan: I mean I think the G7 integration is certainly going to help us. We are seeing very significant interest and excitement right now. It’s only been a week or so. I think that if you talk to the sales organization, they are very pumped up. There is a great deal of interest from the physicians in the marketplace. They are asking to come into their offices and see the product. They have heard about it. As I have said, we have had a number of HCPs. We are part of our early access program who have been speaking about it. And I think it’s going to be a big product for us. It’s going to exceed our expectations, I think. So, we are all very excited about it.
Unidentified Analyst: Thank you.
Operator: Thank you. Our next question comes from Alex Nowak of Craig-Hallum. Your line is open, Alex.
Alex Nowak: Okay. Great. Good afternoon everyone. So, any reason why Mobi didn’t launch with the G7 Libre 3 integration, and it did launch with G6 and Libre 2?
John Sheridan: Well, I think that we have a lot of experience with G6, and we tried to control the number of variables that we are introducing. We wanted to make sure the pump itself is performing as we expected to. And I have to say that it’s been incredible how well the system has performed in the market. So, it’s just a fast follow to get G7 onto it. And this was the intent all along. It’s not that far off now as we are just talking actually weeks or just maybe two months before it’s on the market. So, it’s – I think it was a strategy to make sure that we minimize the variables as the product came to market so we understood exactly how it performed.
Leigh Vosseller: And a point of clarification, Alex, it’s not yet available with Libre 2.
Alex Nowak: It’s not yet. Okay. That’s helpful. A lot of moving pieces with all the integration, so that’s helpful. And then when can we nail down the timelines with – whether it would be Mobi tubeless, t:slim X3 or Sigi, when can we get some real clarification there?
John Sheridan: I think that we are going to be more cautious about discussing timelines for competitive reasons. And I think that we understand the need to have access to that information. So, I think as we get close and we are more confident in the availability and the specific timing, we will share those on future calls.
Alex Nowak: Okay. That sounds good. Thank you so much.
Operator: Thank you. Our next question comes from Joshua Jennings of TD Cowen. Please go ahead, Joshua.
Joshua Jennings: Alright. Thanks for taking the questions. John, I heard you just reference the early experience with Mobi and creating less of a differentiated or gap between tube and tubeless systems and the question basically is, would you have investors think that the Tandem is less reliant on the Sigi patch pump development program for out-year success, or any further follow-up on the comment you made, I think in your prepared remarks in one of your answers on just the size and footprint of Mobi could be more competitive with the tubeless options. Thanks.
John Sheridan: Sure. I mean I think when you look at the portfolio and the specific platforms, we think there is a – I mean there is a need for a patch pump, absolutely. There are people out there that probably would not wear a pump unless it is a patch pump. But we think that the flexibility that comes along with Mobi when it has a tubed and tubeless option as well as the wearability that it has right now, just with the adhesive patch, it’s – it gives people a lot more flexibility, and it almost – it mitigates that tube, tubeless discussion. I think that some people are going to want to wear as a tube pump at certain times in their day. And they are going to also want to wear it as a patch device. And so it gives you that added element of flexibility that either a completely tubed pump or a completely patch pump does it.
And there are people out there that want that flexibility. And so I think that we feel the market research really has indicated that there is a need for the three and that when we have the three, we really do a much better job of addressing the various segments of use out there.
Joshua Jennings: Great. Thanks a lot.
John Sheridan: Thank you, Joshua.
Operator: Thank you. And that does conclude the Q&A portion of our call. That also concludes today’s conference. Thank you for participating. You may now disconnect.
